Home | Meeting coverage | EULAR 2022

Spotlight Discussions RA – ENG

EULAR 2022

F. Behrens, P. Sewerin, E. Choy, T. Kvien, A. Balsa, A. Rubbert-Roth, A. Askari

Updated EULAR RA recommendations: does it change the...

EULAR 2022

F. Behrens, P. Sewerin, E. Choy, T. Kvien, A. Balsa, A. Rubbert-Roth, A. Askari

The road of glucocorticoids in RA

EULAR 2022

F. Behrens, P. Sewerin, E. Choy, T. Kvien, A. Balsa, A. Rubbert-Roth, A. Askari

Prevention of RA possible by treating very early?

Rheumatoid arthritis – ENG

EULAR 2022

Ernest Choy, MD

Rapid tapering of steroids - how quickly should we...

Updated EULAR Recommendations RA, GLORIA

EULAR 2022

Tore Kvien, MD

The significance of depression and air pollution in...

EULAR 2022

Alejandro Balsa, MD

Double-blind placebo controlled trial of MTX in...

TREAT EARLIER

EULAR 2022

Andrea Rubbert-Roth, MD

Analysis of baseline ORAL surveillance data: is it due...

ORAL Surveillance

EULAR 2022

Alejandro Balsa, MD

HOT - Difficulties in treatment of RA

EULAR 2022

Vincent Goëb, MD

Interest of methotrexate before the emergence of RA

TREAT EARLIER

EULAR 2022

Andrea Rubbert-Roth, MD

Can early abatacept therapy in high-risk patients...

ARIAA

EULAR 2022

Tore Kvien, MD

Does MTX have a disease modifying effect in patients...

TREAT EARLIER

EULAR 2022

Alejandro Balsa, MD

Risk of venous thromboembolic events in ORAL...

ORAL Survaillance

EULAR 2022

Andrea Rubbert-Roth, MD

Radiographic progression in RA patients in daily...

RA-BIODAM

Rheumatoid arthritis – GER/FRA/NOR/ESP

EULAR 2022

Tore Kvien, MD

Betydning av depresjon og luftforurensning hos...

EULAR 2022

Vincent Goëb, MD

Interet du méthotrexate avant l´émergence de la PR

TREAT EARLIER

EULAR 2022

Andrea Rubbert-Roth, MD

Liegt es an Vorgeschichte und oder Geographie?

ORAL Surveillance

EULAR 2022

Alejandro Balsa, MD

Abordaje de la artritis reumatoide difícil de tratar

EULAR 2022

Andrea Rubbert-Roth, MD

Frühzeitige Abatacept-Therapie bei Hochrisiko RA...

ARIAA

EULAR 2022

Alejandro Balsa, MD

Riesgo de eventos tromboembolicos en el ORAL...

ORAL Survaillance

EULAR 2022

Andrea Rubbert-Roth, MD

Radiologische Progression ist unabhängig von...

RA-BIODAM

EULAR 2022

Tore Kvien, MD

Har MTX en sykdomsmodifiserende effekt hos pasienter...

TREAT EARLIER

EULAR 2022

Alejandro Balsa, MD

Metotrexate en pacientes con artralgia inflamatoria en...

TREAT EARLIER

EULAR 2022

Philipp Sewerin, MD

MRT auch ohne Kontrastmittel bei RA einsetzbar

Spotlight Discussions SpA – ENG

EULAR 2022

F. Behrens, V. Goëb, T. Kvien, P. Sewerin, F. Ciccia, E. Lubrano, A. Askari

New data on IL-17 inhibition and a 1st in class...

EULAR 2022

F. Behrens, V. Goëb, T. Kvien, P. Sewerin, F. Ciccia, E. Lubrano, A. Askari

The (unmet) need for perspective biomarkers in SpA

EULAR 2022

F. Behrens, V. Goëb, T. Kvien, P. Sewerin, F. Ciccia, E. Lubrano, A. Askari

Hot topic spine: axial diseases in SpA and suitable...

Psoriatic arthritis – ENG

EULAR 2022

Ennio Lubrano, MD

A new treatment for PsA

EULAR 2022

Philipp Sewerin, MD

Course of ultrasound-detected synovitis in PsA patients...

ULTIMATE

EULAR 2022

Philipp Sewerin, MD

Low rates of sustained remission in a real world...

EULAR 2022

Philipp Sewerin, MD

PsA is associated with a higher risk of hematological...

EULAR 2022

Vincent Goëb, MD

Who has the best chance of being in prolonged remission...

EULAR 2022

Frank Behrens, MD

Revival of leflunomide - the combination with MTX

EULAR 2022

Frank Behrens, MD

First in class: new molecule to inhibit IL-17A

EULAR 2022

Frank Behrens, MD

Every joint counts! Even patients with LJC should be...

EULAR 2022

Frank Behrens, MD

Guselkumab "more safe" than Placebo

Discover/Cosmos

EULAR 2022

Ayman Askari, MD

New therapies for PsA

Psoriatic arthritis – FRA/GER/ITA

EULAR 2022

Frank Behrens, MD

Guselkumab "sicherer" als Plazebo

Discover/Cosmos

EULAR 2022

Philipp Sewerin, MD

Verlauf von sonographischer Synovitis unter Secukinumab

ULTIMATE

EULAR 2022

Philipp Sewerin, MD

Geringe Raten an anhaltender Remission im Real Wold...

EULAR 2022

Philipp Sewerin, MD

PsA mit einem höheren Risiko für hämatologische...

EULAR 2022

Frank Behrens, MD

Revival von Leflunomid - in Kombination mit MTX

EULAR 2022

Vincent Goëb, MD

Qui a le plus de chance d´etre en rémission prolongee...

EULAR 2022

Frank Behrens, MD

Jedes Gelenk zählt! Auch bei niedrigem Joint Count...

EULAR 2022

Frank Behrens, MD

Neues Molekül zur Hemmung von IL-17A

EULAR 2022

Ennio Lubrano, MD

Novità nel trattamento dell’Artrite Psoriasica

Axial spondyloarthritis – ENG

EULAR 2022

Xabier Michelena Vegas, MD

New ASAS/EULAR axSpA recommendations

EULAR 2022

Xabier Michelena Vegas, MD

New drugs in axSpA

SELECT-AXIS 2, BE MOBILE 2

EULAR 2022

Xabier Michelena Vegas, MD

Artificial intelligence in axSpA

EULAR 2022

Ennio Lubrano, MD

A deep dive review of axSpA

EULAR 2022

Francesco Ciccia, MD

Rates of progression from non-radiographic to...

Axial spondyloarthritis – ESP/ITA

EULAR 2022

Xabier Michelena Vegas, MD

Nuevos recomendaciones ASAS/EULAR en EspAax

EULAR 2022

Xabier Michelena Vegas, MD

Nuevos terapias en EspAax

SELECT-AXIS 2, BE MOBILE 2

EULAR 2022

Xabier Michelena Vegas, MD

Inteligencia artificial en EspAax

EULAR 2022

Ennio Lubrano, MD

Rivisitazione dell’impegno assiale dell'artrite...

EULAR 2022

Francesco Ciccia, MD

Percentuale di progressione da forma non radiografica a...

Lupus erythematosus – ENG

EULAR 2022

Bimba Franziska Hoyer, MD

Voclosporin for Lupus Nephritis

AURORA-2

EULAR 2022

Bimba Franziska Hoyer, MD

Deucravacitinib for Lupus Erythematosus - Phase II...

Lupus erythematosus – GER

EULAR 2022

Bimba Franziska Hoyer, MD

Voclosporin bei Lupus Nephritis

AURORA-2

EULAR 2022

Bimba Franziska Hoyer, MD

TYK2-Inhibitor Deucravacitinib wirksam und verträglich

COVID-19 – ENG

EULAR 2022

Ayman Askari, MD

Vaccination in rheumatic diseases including COVID-19

EULAR 2022

Tore Kvien, MD

Vaccination response against COVID-19 in patients with...

Nor-vaC study

EULAR 2022

Ayman Askari, MD

Predictive severity factors of COVID-19 in R-IMID...

EULAR 2022

Andrea Rubbert-Roth, MD

Type of mRNA COVID-19 vaccine influences antibody...

COVID-19 – GER/NOR

EULAR 2022

Andrea Rubbert-Roth, MD

Antikörperkinetik unter verschiedenen...

EULAR 2022

Tore Kvien, MD

Vaksine respons (COVID-19) hos pasienter med...

Nor-vaC study

Ankylosing spondylitis – ENG

EULAR 2022

Francesco Ciccia, MD

GM-CSF is increased in patients with AS and persists...

Ankylosing spondylitis – ITA

EULAR 2022

Francesco Ciccia, MD

I livelli di GM-CSF sono incrementati nei pazienti con...

VARIA Highlights – ENG

EULAR 2022

Vincent Goëb, MD

The microbiota to predict the response to the treatment...

EULAR 2022

Ayman Askari, MD

Pain - challenges in clinical practice

EULAR 2022

Ayman Askari, MD

Management of calcific tendonitis by BARBOTAGE

EULAR 2022

Francesco Ciccia, MD

Link between biomechanical stretch and synovial...

EULAR 2022

Ayman Askari, MD

Real-world data of an etanercept biosimilar (GP2015) in...

COMPACT

EULAR 2022

Ayman Askari, MD

New developments in the field of osteoarthristis

VARIA Highlights – FRA/ITA

EULAR 2022

Francesco Ciccia, MD

Legame tra stress biomeccanico e infiammazione...

EULAR 2022

Vincent Goëb, MD

Le microbiote pour prédire la réponse au traitement du...